Drug Trial Radar · NCT00781391
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Mar 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21,105
Actual
Start
Nov 2008
Primary completion
Apr 2013
Study completion May 2013
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- The TIMI Study Group
- First posted
- Oct 29, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to demonstrate the safety and efficacy profile, in two different dose regimens of Edoxaban (DU-176b), (an investigational new drug being tested for the prevention of stroke/systemic embolic events (SEE)), in individuals with atrial fibrillation. Patients will be randomized to one of three treatment groups: High Dose Regimen, Low Dose Regimen, \& Warfarin. The expected duration of the study is 24 months.
Conditions
- Stroke
- Atrial Fibrillation
- Embolism
Interventions
warfarin tabletsDrug
Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
Edoxaban tablets (high dose regimen-60mg)Drug
Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
Edoxaban tablets (low dose regimen-30mg)Drug
Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
placebo warfarinDrug
placebo warfarin
placebo edoxabanDrug
placebo edoxaban
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up
- Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up
- Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: on-treatment period 2.5 years of median study drug exposure and 2.8 year of median follow-up
- Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up
- Compare Edoxaban to Warfarin for Superiority for Composite of Stroke and Systemic Embolic Events (SEE).Time frame: overall study period 2.5 years of median study drug exposure and 2.8 year of median follow-up
Locations
1,009 sites in 46 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Gilbert, Arizona
Site not named
Glendale, Arizona
Site not named
Lake Havasu City, Arizona
Site not named
Sierra Vista, Arizona
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
Harrisburg, Arkansas
Site not named
Hot Springs, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Alhambra, California
Site not named
Anaheim, California
Site not named
Burbank, California
Site not named
Chula Vista, California
Site not named
Encinitas, California
Site not named
Fountain Valley, California
Site not named
Glendale, California
Site not named
Healdsburg, California
Site not named
Lakewood, California
Site not named
Long Beach, California
Site not named
Los Alamitos, California
Site not named
Los Angeles, California
Site not named
Los Banos, California
Site not named
Mather, California
Site not named
Merced, California
Site not named
Newport Beach, California
Site not named
Oceanside, California
Site not named
Pacific Palisades, California
Site not named
Palm Springs, California
Site not named
Pismo Beach, California
Site not named
Redondo Beach, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Santa Rosa, California
Site not named
Torrance, California
Site not named
Ventura, California
Site not named
Aurora, Colorado
Site not named
Colorado Springs, Colorado
Site not named
Denver, Colorado
Showing 40 of 1,009 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.